in this issue
Regions :: Western Europe :: U.K.
Hikma Acquires Stake in Chinese API Manufacturer
4:45 AM MDT | July 12, 2011 | Deepti Ramesh
Hikma Pharmaceuticals (London) says it has acquired a significant minority interest in Hubei Haosun Pharmaceutical through the subscription of new equity for $5 million. Hubei Haosun, a privately held company that develops and manufactures niche, difficult to make active pharmaceutical ingredients (APIs) with a specialization in oncology APIs, is located in the Gedian Economical Development Zone in Hubei province, China. Hubei Haosun operates a U.S. FDA and European Union approved facility and its product portfolio and development pipeline, which covers a range...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee